The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers

Clinical Lung Cancer

Volumn 10, Issue 4, 2009, Pages 262-272

  Camidge, D Ross ^a   Dziadziuszko, Rafal ^b   Hirsch, Fred R ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cixutumumab; Figitumumab; IGF 1R; Insulin receptor; Non small cell lung cancer

Indexed keywords

AMG 479; AVE 1642; BIIB 022; CARBOPLATIN; CISPLATIN; CIXUTUMUMAB; CP 751871; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; EXEMESTANE; FULVESTRANT; GEMCITABINE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; IMC A 12; INSULIN; MK 0646; MONOCLONAL ANTIBODY; PACLITAXEL; R 1507; SCH 717454; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; BREAST CANCER; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; EWING SARCOMA; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPERGLYCEMIA; LIVER CANCER; LOADING DRUG DOSE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOMA; NAIL DISEASE; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PRURITUS; PURPURA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 70349462997     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.037     Document Type: Review

References (63)

1. Chao W, D'Amore PA. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008; 19 : 111-120.
2. Denley A, Wang CC, McNeil KA, et al. Structural and functional characteristics of the Val44Met insulin-like growth factor I missense mutation: correlation with effects on growth and development. Mol Endocrinol 2005; 19 : 711-721.
3. DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64 : 849-859.
4. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195 : 127-137.
5. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007; 6 : 821-833.
6. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors in the fed and fasted states. J Clin Endocrinol Metab 1982; 55 : 999-1002.
7. Minuto F, Palermo C, Arvigo M, Barreca AM. The IGF system and bone. J Endocrinol Invest 2005; 28(suppl):8-10.
8. Reik W, Constancia M, Dean W, et al. Igf2 imprinting in development and disease. Int J Dev Biol 2000; 44 : 145-150.
9. Prawitt D, Enklaar T, Gärtner-Rupprecht B, et al. Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith- Wiedemann syndrome and Wilms' tumor. Proc Natl Acad Sci USA 2005; 102 : 4085-4090.
10. Wolk A, Andersson SO, Mantzoros CS, et al. Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? Lancet 2000; 356 : 1902-1903.
11. Savage MO, Blair JC, Jorge AJ, et al. IGFs and IGFBPs in GH insensitivity. Endocr Dev 2005; 9 : 100-106.
12. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16 : 3-34.
13. Hartog H, Wesseling J, Boezen HM, et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007; 43 : 1895-904.
14. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6 : 1-12.
15. Siddle K, Ursø B, Niesler CA, et al. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 2001; 29 : 513-525.
16. Tao Y, Pinzi V, Bourhis J, et al. Mechanisms of disease: signaling of the insulinlike growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007; 4 : 591-602.
17. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006; 94 : 465-468.
18. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008; 4 : 33-43.
19. Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord 2008; 9 : 41-58.
20. Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113 : 5-21.
21. Cheng I, Stram DO, Penney KL, et al. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 2006; 98 : 123-134. (Pubitemid 43159967)
22. Quinn KA, Unsworth EJ, Miller MJ, et al. Insulin-like growth factor expression in human lung and breast cancer cell lines. J Biol Chem 1996; 271 : 11477-11483.
23. Stawowy P, Kallisch H, Kilimnik A, et al. Proprotein convertases regulate insulin- like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor. Biochem Biophys Res Commun 2004; 321 : 531-538.
24. Donovan EA, Kummar S. Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol 2008; 66 : 91-98.
25. Ravenel JD, Broman KW, Perlman EJ, et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 2001; 93 : 1698-1703.
26. Moorehead RA, Sanchez OH, Baldwin RM, et al. Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene 2003; 22 : 853-857.
27. Velcheti V, Govindan R. Insulin-like growth factor and lung cancer. J Thorac Oncol 2006; 1 : 607-610.
28. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004; 24 : 7275-7283.
29. Werner H, Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol Metab 2006; 17 : 236-242. (Pubitemid 44080616)
30. Kim HJ, Litzenburger BC, Cui X, et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 2007; 27 : 3165-3175.
31. Carboni JM, Lee AV, Hadsell DL, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005; 65 : 3781-3787.
32. Samani AA, Yakar S, LeRoith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28 : 20-47.
33. Kong FM, Anscher MS, Washington MK, et al. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 2000; 19 : 1572-1578.
34. Vaira V, Lee CW, Goel HL, et al. Regulation of survivin expression by IGF-1/ mTOR signaling. Oncogene 2007; 26 : 2678-2684.
35. Oh SH, Jin Q, Kim ES, et al. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res 2008; 14 : 1581-1589.
36. Allen GW, Saba C, Armstrong EA, et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 2007; 67 : 1155-1162.
37. Rochester MA, Riedemann J, Hellawell GO, et al. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005; 12 : 90-100.
38. Goetsch L, Gonzalez A, Leger O, et al. A recombinant humanized anti-insulinlike growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005; 113 : 316-328.
39. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11 : 793-814.
40. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62 : 200-207.
41. Morgillo F, Kim WY, Kim ES, et al. Implication of the insulin-like growth factor- IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007; 13 : 2795-2803.
42. Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13:5549s-5555s.
43. Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65 : 11118-11128.
44. Rubini M, Hongo A, D'Ambrosio C, et al. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res 1997; 230 : 284-292.
45. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871. Clin Cancer Res 2005; 11 : 2063-2073.
46. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13 : 5834-5840.
47. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751, 871 in patients with multiple myeloma. J Clin Oncol 2008; 26 : 3196-3203.
48. de Bono JS, Attard G, Adjei A, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007; 13 : 3611-3616.
49. Pollak MN, Lacy MQ, Lipton A, et al. Pharmacodynamic properties of the anti- IGF-IR monoclonal antibody CP-751, 871 in cancer patients. J Clin Oncol 2007; 25(18 suppl):159s (Abstract 3587).
50. Karp DD, Paz-Ares LG, Novello S, et al. High activity of the anti-IGF-IR antibody CP-751, 871 in combination with paclitaxel and carboplatin in squamous NSCLC. J Clin Oncol 2008; 26(15 suppl):427s (Abstract 8015).
51. Karp DD, Paz-Ares LG, Blakely LJ, et al. Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18 suppl):386s (Abstract 7506).
52. Rodon J, Patnaik A, Stein M, et al. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol 2007; 25(18 suppl):160s (Abstract 3590).
53. Leong S, Gore L, Benjamin R, et al. A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Octo ber 22-26, 2007; San Francisco, California. Abstract A78.
54. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic and pharmacodynamic study of weekly MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody in patients with advanced solid tumors. J Clin Oncol 2008; 26(15 suppl):157s (Abstract 3519).
55. Olmos D, Okuno S, Schuetze SM, et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751, 871 in patients with sarcoma. J Clin Oncol 2008; 26(15 suppl):553s (Abstract 10501).
56. Tolcher AW, Rothenberg ML, Rodon J, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007; 25(18 suppl):118s (Abstract 3002).
57. Sarantopoulos J, Mita AC, Mulay M, et al. A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab or gemcitabine. J Clin Oncol 2008; 26(15 suppl):173s (Abstract 3583).
58. Higano CS, Yu EY, Whiting SH, et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 2007; 25(18 suppl):139s (Abstract 3505).
59. Hidalgo M, Tirado Gomez M, Lewis N, et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 2008; 26(15 suppl)158s (Abstract 3520).
60. Tolcher AW, Patnaik A, Till E, et al. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients with advanced solid tumor. J Clin Oncol 2008; 26(18 suppl):173s (Abstract 3582).
61. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007; 6 : 2158-2167.
62. Sachdev D, Hartell JS, Lee AV, et al. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 2004; 279 : 5017-5024.
63. Gualberto A, Melvin CL, Dean A, et al. Characterization of NSCLC patients responding to anti-IGF-IR therapy. J Clin Oncol 2008; 26(15 suppl):424s (Abstract 8000).